Introduction {#s1}
============

Friedreich ataxia (FRDA; OMIM\# 229300) is the most common autosomal-recessively inherited ataxia that begins in childhood and leads to death in early adulthood. Patients exhibit neurodegeneration of the large sensory neurons and spinocerebellar tracts, along with variable systemic manifestations that include hypertrophic cardiomyopathy, scoliosis, and diabetes mellitus. FRDA results from the partial loss of frataxin (*FXN*; Entrez Gene ID 2395), a small nuclear-encoded 18-kDa protein targeted to the mitochondrial matrix [@pone.0094069-Campuzano1].

The mitochondrion is supported by the 37 mitochondrial DNA (mtDNA)-encoded genes, which are transcribed in two polycistrones regulated by the heavy- and light-strand promoters [@pone.0094069-Bonawitz1]. Thirteen of these genes encode for protein subunits of the oxidative phosphorylation (OXPHOS) machinery, which are known to closely interact with nuclear DNA (nDNA)-encoded subunits within four of the five OXPHOS complexes (complexes I, III, IV and V). The mutation rate of the coding mtDNA is higher by an order of magnitude than that of most coding nDNA [@pone.0094069-Grossman1], [@pone.0094069-Mishmar1].

Most patients with FRDA have a pathogenic expansion of a trinucleotide repeat (GAA) within the first intron of the *FXN* gene, which is located on chromosome locus 9q13 [@pone.0094069-Campuzano1], [@pone.0094069-Harding1], [@pone.0094069-Campuzano2], that impairs the transcription of frataxin, resulting in a significant reduction in mRNA and protein levels [@pone.0094069-Ohshima1]. Less than 5% of patients with FRDA are compound heterozygotes with the GAA repeat in one allele and a frataxin point mutation, including missense, nonsense, or intronic mutations, in the other allele [@pone.0094069-Cosse1]. FRDA affects 1 in every 50,000 people [@pone.0094069-Tan1], in which among affected individuals, the Caucasian and South Asian populations are overrepresented. In the general population, the repeat length is 30, while in FRDA patients the repeat length ranges from 66 to 1700 [@pone.0094069-Campuzano2], [@pone.0094069-Cosse2].

Iron-sulfur (Fe-S) clusters (ISC) are essential cofactors of proteins that perform important functions, such as electron transfer, catalysis, DNA repair, tRNA thiolation, ribosome biogenesis, and iron regulation [@pone.0094069-Stemmler1]--[@pone.0094069-Lill1]. Fe-S cluster biogenesis occurs in the mitochondria, and disruption of the process, caused by frataxin deficiency, is associated with human diseases such as FRDA and diabetes [@pone.0094069-Campuzano2]. Loss of frataxin function, therefore, can result in ISC-containing protein deficiency, decreasing mitochondrial respiratory chain activity [@pone.0094069-Rtig1], accumulation of iron in affected organs [@pone.0094069-Zecca1], faulty iron handling and impaired ISC synthesis [@pone.0094069-Rtig1]. Thus, a decrease in frataxin may also increase reactive oxygen species (ROS) produced by an increase in bioavailable iron [@pone.0094069-Mhlenhoff1], [@pone.0094069-Shoichet1], and the lack of iron detoxification [@pone.0094069-Gakh1]. Dysfunctional biosynthesis of mitochondrial iron-sulfur clusters and deficiency of ISC enzyme activity produces a defect in heme, which in turn causes a loss of cytochrome C. Electron transport activity impairment results in higher levels of ROS production [@pone.0094069-Napoli1], [@pone.0094069-Calabrese1]. Defects in ISC assembly is the primary event in frataxin-deficient cells [@pone.0094069-Puccio1], while ROS production is a secondary event [@pone.0094069-Yang1].

Clinically, FRDA is characterized by multiple symptoms, including progressive gait and limb ataxia, dysarthria, diabetes mellitus and hypertrophic cardiomyopathy [@pone.0094069-Mateo1]. There is intramitochondrial iron accumulation in the heart, liver, nervous system and spleen of FRDA patients, as well as reduction in mitochondrial DNA, the Fe-S cluster-containing subunits of the mitochondrial electron transport chain (complex I--III), and the enzyme aconitase [@pone.0094069-Bradley1], [@pone.0094069-Bulteau1].

Complex I deficiency is the most common cause of respiratory chain dysfunction, accounting for 50% of all cases. Pathogenic mutations have been identified in nuclear genes that encode both complex I structural subunits and complex I assembly factors, and in all seven of the complex I mtDNA-encoded subunit genes [@pone.0094069-McKenzie1]. Mitochondrial respiratory complex I deficiency and oxidative stress have been reported to occur in this disease, but mtDNA and nDNA that encode for the subunits of the chain complex could be considered a candidate modifier factor for FRDA disease [@pone.0094069-Heidari1].

The coordinated expression of known OXPHOS genes goes beyond a mitochondrial or even OXPHOS pattern of expression, to the level of individual complexes, in which the levels of mRNA are influenced by common promoter elements or a feedback mechanism from the assembled complexes [@pone.0094069-vanWaveren1]. Furthermore, It has been suggested that the regulation of expression of the OXPHOS complex I subunits in humans is complex and tends to undergo divergence of sub-clustered expression, rather than reflect global co-regulation [@pone.0094069-Garbian1].

In this study, the expression pattern profiles of NDUFA4, one of the nDNA-encoded subunits of complex IV, and 16 mitochondrial complex I subunits, including 7 mtDNA and 9 nDNA-encoded subunits, were analyzed in FRDA patients in order to determine whether the complex I genes were expressed through co-regulation or through sub-clustering.

Materials and Methods {#s2}
=====================

Specimen Collection and Ethical Statement {#s2a}
-----------------------------------------

Twenty-one FRDA patients, including 9 females and 12 males with a mean age of 17.8 years from 16 unrelated families, were diagnosed with clinical features that are summarized in [Table 1](#pone-0094069-t001){ref-type="table"}. Blood samples from 21 FRDA patients and 24 random individuals of mixed ethnicities (as healthy controls) were obtained from the Special Medical Center, Tehran, Iran.

10.1371/journal.pone.0094069.t001

###### Clinical characteristics of the 21 FRDA patients.

![](pone.0094069.t001){#pone-0094069-t001-1}

  No. of Patients    Gender   Consanguineous marriages   History of family   Age of onset   Age of Diagnosis   Limb Ataxia   Lower-Limb Areflexia   Decreased Vibration Sense   Extensor Plantar Response   Axonal Neuropathy   Dysarthri   Eye Movement Abnormality\*   Optic Atrophy   Food Deformity   Diabetes or Glucose Intolerance   GAA Repeat
  ----------------- -------- -------------------------- ------------------- -------------- ------------------ ------------- ---------------------- --------------------------- --------------------------- ------------------- ----------- ---------------------------- --------------- ---------------- --------------------------------- ------------
  FRDA 01              F                None                     4                13               17              \+                 \+                       \+                          \+                      \+              \+                   N                     \_               \+                       \_                     384
  FRDA 02              M               First                     1                11               13              \+                 \+                       \+                          \+                      \+              \+                   N                     \_               \+                       \_                     329
  FRDA 03              M               First                     1                14               16              \+                 \+                       \+                          \+                      \+              \+                   N                     \_               \+                       \_                     426
  FRDA 04              M                None                     7                12               25              \+                 \+                       \+                          \+                      \_              \+                   DS                    \_               \_                       \_                     566
  FRDA 05              M                None                     7                17               21              \+                 \+                       \+                          \+                      \+              \+                   DS                    \_               \+                       \_                     269
  FRDA 06              M                None                     7                7                19              \+                 \+                       \_                          \+                      \_              \+                   N                     \_               \_                       \_                     890
  FRDA 07              M                None                     1                5                21              \+                 \+                       \_                          \+                      \_              \+                  SWJ                    \_               \_                       \_                     947
  FRDA 08              M                None                     1                6                19              \+                 \+                       \_                         None                     \_              \+                   \_                    \_               \_                       \_                     878
  FRDA 09              F               First                   None               12               16              \+                 \+                       \_                          \+                      \_              \+                  SWJ                    \+               \_                       \_                     498
  FRDA 10              M                None                     1                23               29              \+                 \+                       \_                          \+                      \+              \+                   DS                    \_               \+                       \_                     247
  FRDA 11              M                None                     1                15               19              \+                 \+                       \_                         None                     \_              \+                   \_                    \_               \_                       \_                     584
  FRDA 12              M                None                     1                15               15              \+                 \+                       \+                          \+                      \_              \_                   \_                    \_               \_                       \_                     618
  FRDA 13              F               First                   None               6                25              \+                 \+                       \+                          \+                      \+              \+                   N                     \_               \+                       \_                     908
  FRDA 14              F                None                     3                13               28              \+                 \+                       \_                          \+                      \+              \+                   N                     \_               \+                       \_                     405
  FRDA 15              F                None                     1                2                4               \+                 \+                       \+                          \+                      \+              \+                   N                     \_               \+                       \_                     981
  FRDA 16              M               First                     1                12               26              \+                 \+                       \+                          \+                      \+              \+                   N                     \_               \+                       \_                     432
  FRDA 17              F                None                   None               3                8               \+                 \+                       \_                          \+                      \_              \+                   DS                    \+               \_                       \+                     812
  FRDA 18              F               First                     2                13               16              \+                 \+                       \+                          \+                      \+              \+                   DS                    \_               \+                       \_                     479
  FRDA 19              F               First                     2                9                10              \+                 \+                       \+                          \+                      \+              \+                   N                     \_               \+                       \_                     554
  FRDA 20              M               First                     1                15               17              \+                 \+                       \+                          \+                      \_              \+                   N                     \_               \_                       \_                     360
  FRDA 21              F                None                     1                8                10              \+                 \+                       \+                          \+                      \_              \+                  SWJ                    \_               \_                       \_                     714

\*N: Nystagmus; DS: Dysmetric Saccades; SWJ: Square Wave Jerks.

The exclusion criterion for the healthy control group was any history of cancer, metabolic diseases or mitochondrial DNA-related diseases that may affect mtDNA and nDNA. Written informed consent, including consent to participate in the study and consent to publish, was obtained from the patients, parents on behalf of children, and healthy controls for the present study in accordance with the Special Medical Center and Medical Ethics Committee (Approval No. FF-18-2007).

RNA Extraction and cDNA Synthesis {#s2b}
---------------------------------

RNA was extracted using the High Pure RNA Isolation Kit (Roche, Germany) and the products were transferred to −80°C for storage. Total cDNA was produced using the RevertAid First Strand cDNA Synthesis Kit (Fermentas, USA), according to the manufacturer\'s protocol. The products were transferred to −20°C for storage. The cDNA was used for subsequent real time-PCR amplification of the nDNA-encoded NDUFA1, NDUFA4, NDUFA5, NDUFA10, NDUFA12, NDUFB10, NDUFB11, NDUFS2, NDUFC2, NDUFV1 genes, and the mtDNA-encoded ND1, ND2, ND3, ND4, ND4L, ND5 and ND6 genes. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and beta--actin (B-ACT) were used as the reference genes for gene expression analysis. The real time-PCR products were transferred to −20°C for storage.

Real time-PCR Analysis {#s2c}
----------------------

Relative quantification of the transcript levels of the genes encoding for the nDNA and mtDNA subunits of complex I and NDUFA4, a subunit from complex IV, was investigated using real time-PCR ([Table 2](#pone-0094069-t002){ref-type="table"}). 100--300 ng of cDNA from the 21 patients and 24 controls were subjected to real time-PCR amplifications in 20 μl reactions containing 1X Absolute SYBER Green ROX Mix, Thermo and 100 nM of each specific primer ([Table 3](#pone-0094069-t003){ref-type="table"}). All primer pairs were initially tested via standard RT-PCR using the same conditions as described for real-time RT-PCR. Amplification of single products of expected size was verified by electrophoresis on 3% agarose gel and ethidium bromide staining (data not shown). The real time-PCR amplifications were carried out in a Rotor-Gene 6000 (Corbett) Real Time-PCR machine with the following protocol: 15 seconds at 95°C, followed by 40 cycles of denaturation for 30 seconds at 95°C, annealing for 1 minute at 60°C and extension for 30 seconds at 72°C. Each experiment was performed in duplicate tubes, and was repeated three times. To control for DNA contamination in the reaction mix, control tubes lacking DNA templates were included in duplicates, with the relevant set of primers in each experiment. Standard curves were generated in triplicates for each primer using ten-fold serial dilutions of a cDNA sample prepared from total RNA. PCR amplifications were also done without cDNA template, as negative control, to monitor the reagents utilized in the assay for possible contamination. The efficiencies of the eighteen pairs of primers were calculated. To determine their amplicon specificity, electrophoresis analysis of the real time-PCR products was also carried out. The real time-PCR Rotor-Gene 6000 software was used to determine the amplification cycle in which product accumulation was above the threshold (Ct). Real time-PCR Ct values (see [Tables 4](#pone-0094069-t004){ref-type="table"} and [5](#pone-0094069-t005){ref-type="table"}) were analyzed using the 2^−ΔΔCt^ method [@pone.0094069-Livak1]. In each experiment, the mean Ct of duplicate tubes for a given gene was normalized to the mean Ct value of the reference gene (GAPDH). A1, A4, A5, A10, A12, B10, B11, S2, C2, V1 are abbreviations of the the nDNA-encoded NDUFA1, NDUFA4, NDUFA5, NDUFA10, NDUFA12, NDUFB10, NDUFB11, NDUFS2, NDUFC2, NDUFV1 genes, respectively. Additionally, the expression levels of the nuclear NDUFA5 and NDUFB10 genes and the mitochondrial ND1 and ND5 genes of complex I were investigated using B-ACT as a housekeeping gene (see [Figures 1](#pone-0094069-g001){ref-type="fig"}, [2](#pone-0094069-g002){ref-type="fig"}, [3](#pone-0094069-g003){ref-type="fig"}, and [4](#pone-0094069-g004){ref-type="fig"}), in order to confirm the reliability of the results achieved with GAPDH as a housekeeping gene ([Table 5](#pone-0094069-t005){ref-type="table"}).

![Gene expression pattern profiling of the nuclear and mitochondrial complex I genes as well as NDUFA4 from complex IV in FRDA patients compared to controls.](pone.0094069.g001){#pone-0094069-g001}

![The mean Ct values of the nuclear and mitochondrial complex I genes as well as NDUFA4 from complex IV in FRDA patients compared to controls.](pone.0094069.g002){#pone-0094069-g002}

![The melting curves of the nuclear and mitochondrial complex I genes as well as NDUFA4 from complex IV in FRDA patients compared to controls.](pone.0094069.g003){#pone-0094069-g003}

![The nDNA and mtDNA gene expression profiles of complex I.\
The NDUFA1 nuclear gene and ND2, ND4L and ND6 mitochondrial genes of complex I were significantly (*p*\<0.05) decreased in FRDA patients compared to controls.](pone.0094069.g004){#pone-0094069-g004}

10.1371/journal.pone.0094069.t002

###### The tested complex I subunits, their genome affiliation (mtDNA or nuclear DNA), and their location in complex I/IV, as well as NDUFA4 from complex IV.
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  Complex I/IV    Gene Name   Locus (mtDNA/nDNA)      Location
  -------------- ----------- -------------------- -----------------
  Complex I                                       
                   NDUFA1            nDNA          Hydrophobic arm
                   NDUFA5            nDNA          Hydrophilic arm
                   NDUFA10           nDNA          Hydrophobic arm
                   NDUFA12           nDNA          Hydrophilic arm
                   NDUFB10           nDNA          Hydrophobic arm
                   NDUFB11           nDNA          Hydrophobic arm
                   NDUFC2            nDNA          Hydrophobic arm
                   NDUFS2            nDNA          Hydrophilic arm
                   NDUFV1            nDNA          Hydrophilic arm
                     ND1            mtDNA          Hydrophobic arm
                     ND2            mtDNA          Hydrophobic arm
                     ND3            mtDNA          Hydrophobic arm
                     ND4            mtDNA          Hydrophobic arm
                    ND4L            mtDNA          Hydrophobic arm
                     ND5            mtDNA          Hydrophobic arm
                     ND6            mtDNA          Hydrophobic arm
  Complex IV                                      
                   NDUFA4            nDNA          Hydrophobic arm

10.1371/journal.pone.0094069.t003

###### Real time-PCR primers of selected nuclear and mitochondrial genes.
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  Gene Name                        Primer Sequences                        PCR Efficiency (%)   Tm (°C)   Amplicon Size (bp)
  ----------- ----------------------------------------------------------- -------------------- --------- --------------------
  NDUFA1              F:ATGTGGTTCGAGATTCTCC R:GCAACCCTTTTTTCCTTGC                97.60           82.69           116
  NDUFA4           F:CAGAGCCCTGGAACAAACTGGG R:GACCTTCATTCTAAAGCAGCG              96.69           76.82           137
  NDUFA5         F:GAGAAGCTGGCTATGGTTAAAGCG R:CCACTAATGGCTCCCATAGTTTCC           96.18           77.18           154
  NDUFA10          F: CACCTGCGATTACTGGTTCAG R:GCAGCTCTCTGAACTGATGTA              97.22           78.73           130
  NDUFA12            F:ACATTCTGGGATGTGGATGG R:CTAGTGGTAGAATAAGGTAC               96.69           77.21           156
  NDUFB10           F:TAGAGCGGCAGCACGCAAAG R:CTGACAGGCTTTGAGCCGATC               100.78          82.23           188
  NDUFB11         F:GGAAAGCGGCCCCCAGAACCGAC R:CCACGCTCTTGGACACCCTGTGC            99.34           82.46           231
  NDUFC2              F:GGTTTGCATCGCCAGCTTC R:CAGGAAAATCCTCTGGATG                102.47          75.87           137
  NDUFS2             F:ACCCAAGCAAAGAAACAGCC R:AATGAGCTTCTCAGTGCCTC               97.22           83.30           214
  NDUFV1             F:TGAGACGGTGCTGATGGACTTC R:AGGCGGGCGATGGCTTTC               99.34           85.22           113
  ND1           3439H:CTACTACAACCCTTCGCTGAC 3655L:GGATTGAGTAAACGGCTAGGC          99.44           79.53           216
  ND2           4892H:CATATACCAAATCTCTCCCTC 5166L:GTGCGAGATAGTAGTAGGGTC          90.08           77.85           274
  ND3          10166H:TTACGAGTGCGGCTTCGACC 11455L:CCTAGTTTTAAGAGTACTGCG          90.64           78.19           189
  ND4          11269H:CTAGGCTCACTAAACATTCTA 11455L:CCTAGTTTTAAGAGTACTGCG         96.74           77.23           186
  ND4L          10528H:TAGTATATCGCTCACACCTC 10726L:GTAGTCTAGGCCATATGTG           96.63           81.33           198
  ND5           3627H:TCGAATAATTCTTCTCACCC 13725L:TAGTAATGAGAAATCCTGCG           96.37           77.70            98
  ND6             14359H:GTAGGATTGGTGCTGTGG 4258L:GGATCCTCCCGAATCAAC             97.98           77.75           119
  GAPDH              F:GAAGGTGAAGGTCGGAGTC R:GAAGATGGTGATGGGATTTC                99.35           80.78           200
  B-ACT              F:CGCGAGAAGATGACCCAGAT R:TCACCGGAGTCCATCACGAT               99.12           83.64           126

The PCR efficiency, melting temperature and amplicon size of the nuclear and mitochondrial complex I genes as well as NDUFA4 from complex IV.

10.1371/journal.pone.0094069.t004

###### Summary of Real time-PCR results with GAPDH and B-ACT as reference genes.
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  Reference Gene    Gene Name   Ct Tg patient   Ct Tg Control   ΔCt TG   Ct HK patient   Ct HK Control   ΔCt HK   ΔΔCt    2^−(ΔΔCt)^
  ---------------- ----------- --------------- --------------- -------- --------------- --------------- -------- ------- ------------
  **GAPDH**                                                                                                              
                       ND1          23.6            25.75       −2.15        21.53           23.11       −1.58    −0.57      1.5
                       ND2          23.39           21.78        1.61        21.53           23.11       −1.58    3.19       0.1
                       ND3          19.63           22.02       −2.39        21.53           23.11       −1.58    −0.81      1.8
                       ND4          19.92           20.78       −0.86        21.53           23.11       −1.58    0.72       0.6
                      ND4L          18.69           19.07       −0.38        21.53           23.11       −1.58     1.2       0.4
                       ND5          21.37           23.75       −2.38        21.53           23.11       −1.58    −0.8       1.7
                       ND6          19.61           19.35        0.26        21.53           23.11       −1.58    1.84       0.3
                     NDUFA1         23.86           24.07       −0.21        21.53           23.11       −1.58    1.37       0.4
                     NDUFA4         22.86           24.25       −1.39        21.53           23.11       −1.58    0.19       0.9
                     NDUFA5         26.07           27.86       −1.79        21.53           23.11       −1.58    −0.21      1.2
                     NDUFA10        24.55           26.48       −1.93        21.53           23.11       −1.58    −0.35      1.3
                     NDUFA12        25.53           27.35       −1.82        21.53           23.11       −1.58    −0.24      1.2
                     NDUFB10        23.63           25.85       −2.22        21.53           23.11       −1.58    −0.64      1.6
                     NDUFB11        25.04           26.75       −1.71        21.53           23.11       −1.58    −0.13      1.1
                     NDUFC2         23.6            25.58       −1.98        21.53           23.11       −1.58    −0.4       1.3
                     NDUFS2         24.66           26.44       −1.78        21.53           23.11       −1.58    −0.2       1.1
                     NDUFV1         23.86           25.75       −1.89        21.53           23.11       −1.58    −0.31      1.2
  **B-ACT**                                                                                                              
                       ND1          22.87           26.05       −3.18        22.36           23.85       −1.49    −1.69      3.2
                       ND5          18.7            19.08       −0.38        22.36           23.85       −1.49    1.11       0.5
                       A5           26.07           28.01       −1.94        22.36           23.85       −1.49    −0.45      1.4
                       B10          24.27           26.38       −2.11        22.36           23.85       −1.49    −0.62      1.5

10.1371/journal.pone.0094069.t005

###### Statistical analysis of the nuclear and mitochondrial complex I and IV genes.
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  Reference Gene     Genes    Patients/Controls   *p*- value
  ---------------- --------- ------------------- ------------
  **GAPDH**                                      
                    NDUFA1          21/24          0.0445\*
                    NDUFA4          21/24           0.1262
                    NDUFA5          21/24           0.0566
                    NDUFA10         21/24           0.2170
                    NDUFA12         21/24           0.0622
                    NDUFB10         21/24           0.0917
                    NDUFB11         21/24           0.1878
                    NDUFC2          21/24           0.1338
                    NDUFS2          21/24           0.0717
                    NDUFV1          21/24           0.1603
                      ND1           21/24           0.1256
                      ND2           21/24          0.0033\*
                      ND3           21/24           0.0674
                      ND4           21/24           0.2075
                     ND4L           21/24          0.0333\*
                      ND5           21/24           0.1330
                      ND6           21/24          0.0037\*
  **B-ACT**                                      
                    NDUFA5          21/24           0.4212
                    NDUFB10         21/24           0.1056
                      ND1           21/24           0.0941
                      ND5           21/24           0.1597

The nDNA and mtDNA genes are normalized to GAPDH in FRDA patients compared to controls. The expression levels of four selected nDNA (NDUFA5 and NDUFB10) and mtDNA (ND1 and ND5) genes were normalized to B-ACT as a housekeeping gene in order to confirm the consistency of the result to those observed with GAPDH for quantitative gene expression analysis (*P*\>0.05).

Statistical significance is expressed as \**P*\<0.05 *vs* controls.

Statistical analysis {#s2d}
--------------------

Unpaired t-test analysis was used to examine the association between FRDA patients and healthy control groups, where *p*\<0.05 is regarded as statistically significant. Statistical analysis was performed using Microsoft Office Excel 2010 and GraphPad Prism 6.0 software.

Results {#s3}
=======

The presence of GAA repeat expansions on both alleles in 21 FRDA patients, including 12 males and 9 females, were confirmed using PCR. The gene expression of the nuclear and mitochondrial DNA genes encoding for complex I subunits were profiled using real time-PCR and the relative expression patterns of genes were normalized with GAPDH as the housekeeping gene. In order to evaluate amplification specificity and efficiency, electrophoresis was performed for the real time-PCR amplicons, where only a single band of the respective expected PCR product sizes were observed (data not shown).

Gene expression analysis was performed using the relative quantification method and compared to controls according to the Livak method [@pone.0094069-Livak1] as summarized in [Table 4](#pone-0094069-t004){ref-type="table"}. Additionally, the Ct range was assessed and the coefficient of variance for each gene across all samples was calculated in order to reveal the differences in transcript levels between the 17 nDNA and mtDNA genes.

In this study, the transcript levels of most mtDNA-encoded genes were lower than the transcript levels of the nDNA-encoded genes ([Figure 1](#pone-0094069-g001){ref-type="fig"}). However, the transcript variations of mtDNA-encoded genes were higher than that of the nDNA-encoded genes ([Figure 2](#pone-0094069-g002){ref-type="fig"}). The melting temperatures (Tm) of all PCR products ranged from 77.21°C for NDUFA12 to 85.22°C for NDUFV1 ([Figure 3](#pone-0094069-g003){ref-type="fig"}). The amplification efficiency of the primers varied from 90.08% for ND2 to 102.47% for NDUFC2. No primer dimers or non-specific amplification were observed. The PCR efficiency, melting temperature and amplicon size of selected genes are summarized in [Table 3](#pone-0094069-t003){ref-type="table"}.

Our results indicated that there were significant differences at the transcript level between the nDNA and mtDNA subunit genes of complex I in patients compared to controls ([Table 5](#pone-0094069-t005){ref-type="table"}). Specifically, mtDNA-encoded ND2, ND4L, and ND6 genes indicated significantly lower (*p*\<0.05) gene expression than most of the other mtDNA-encoded genes in patients compared to controls, in which ND2 demonstrated the lowest relative gene expression level as compared to most of the mtDNA- and nDNA-encoded genes in patients compared to controls. Additionally, the relative gene expression level of the nDNA-encoded NDUFA1 subunit gene was lowest (*p*\<0.05) compared to most of the nDNA-encoded genes in patients compared to controls and was expressed at a level similar to the mtDNA-encoded ND4L subunit gene in patients ([Figure 4](#pone-0094069-g004){ref-type="fig"}).

Discussion {#s4}
==========

In this study, in order to identify the subset of key genes responsible for the clinical phenotype seen in FRDA patients, the gene expression profiles of OXPHOS complex I genes in patients were compared to the control groups. We hypothesized that mitochondrial and nuclear genes that encode for oxidative phosphorylation (OXPHOS) complex I subunits tend to undergo divergence and have sub-clustered expression rather than co-regulation. As previously reported, the transcription of many OXPHOS genes in type 2 diabetes mellitus, a metabolic disorder, is governed by co-regulation [@pone.0094069-Stuart1], [@pone.0094069-Mootha1], while another study revealed that the regulation of OXPHOS complex I subunit gene expression in humans is complex rather than reflecting global co-regulation [@pone.0094069-Garbian1]. Therefore, to examine gene expression as a co-regulation or sub-clustering mechanism, the 16 complex I subunit transcripts, including all seven mtDNA-encoded and nine nDNA-encoded subunits of complex I genes were investigated in FRDA patients. Additionally, one of the nDNA-encoded complex IV structural subunit genes, NDUFA4, formerly considered as a constituent of the complex I subunit, was also examined in this study [@pone.0094069-Balsa1].

Our findings showed the existence of two clusters of expression profiles in the OXPHOS complex I subunit genes, including all the mtDNA-encoded subunit genes and most of the tested nDNA-encoded subunit genes, where the mtDNA-encoded subunit genes are the major contributors to the divergence compared to the nDNA-encoded subunit genes, with co-regulated expression.

FRDA is caused by a GAA trinucleotide expansion in the first intron of the frataxin gene [@pone.0094069-Cosse2], leading to reduced expression of the mitochondrial protein frataxin. Frataxin is critically involved in iron sulfur cluster assembly, iron homeostasis [@pone.0094069-Campuzano1], [@pone.0094069-Cosse1], and is a controller of intracellular oxidative stress by modulating the concentration of ROS [@pone.0094069-ChantrelGroussard1]. In agreement with previous studies [@pone.0094069-Campuzano1], [@pone.0094069-Cond1], [@pone.0094069-Pianese1], our investigation revealed homozygous GAA triplet repeat expansions within the first intron of the *FXN* gene. Additionally, our results are clinically in line with previous studies [@pone.0094069-Campuzano1], [@pone.0094069-Campuzano2], [@pone.0094069-Tan1], showing that FRDA is determined by progressive ataxia of gait and extremities, dysarthria and areflexia. Muscle weakness is evident particularly in the lower limbs, though signs of weakness or fatigue may be masked by more prominent features of FRDA.

It is noteworthy to mention that the frataxin is particularly abundant in tissues that are rich in mitochondria, such as liver, heart, pancreas, muscle, brown fat, thymus and kidney [@pone.0094069-Campuzano2], [@pone.0094069-Koutnikova1], [@pone.0094069-Puccio2]. However, the choice of blood samples in the present study was due to scarce availability of the main target tissues. FRDA patients with low levels of frataxin may have heteroplasmic mtDNA mutations, where the combination of mitochondrial mutations, altered proteins, excess iron and increased ROS could contribute significantly to the disease state [@pone.0094069-Karthikeyan1]. Deficiencies in the activities of the iron-sulfur cluster (ISC)-dependent aconitase, neural and cardiac cell degeneration as well as mitochondrial respiratory chain complexes I, II and III have been demonstrated in FRDA patients [@pone.0094069-Heidari2].

Accumulation and imbalance of iron can lead to oxidative stress, the generation of ROS and severe mitochondrial damage. Formation of ROS as a by-product of the OXPHOS process results in damaged DNA, RNA, proteins and lipids in many degenerative diseases, cancer and aging [@pone.0094069-Karthikeyan1]. Frataxin deficiency causes more sensitivity to oxidative stress [@pone.0094069-Cond1], mtDNA and nDNA instability, chromosomal mutations and enhanced recombination rates, probably through hydrogen peroxide intermediates [@pone.0094069-Karthikeyan1].

Mitochondrial diseases with defects in the OXPHOS system are mediated by mutations in either nDNA or mtDNA, and therefore have distinct patterns of inheritance, depending on the genetic origin [@pone.0094069-Diaz1]. Complex I deficiency is the most common defect of the mitochondrial OXPHOS system, which accounts for about one third of all cases of OXPHOS disorders [@pone.0094069-Tucker1]. Analyses of complex I deficiency have revealed mutations in some nDNA-encoded and mtDNA subunit genes in OXPHOS disorders [@pone.0094069-Diaz1]. Our study showed the significant down-regulation of the nDNA-encoded subunit gene NDUFA1 and three mtDNA complex I genes ND2, ND4L and ND6 in FRDA patients compared to controls. A microarray-based analysis indicated evidence for co-transcription of OXPHOS genes, showing the preference of subunits of each OXPHOS complex to cluster separately [@pone.0094069-vanWaveren1]. It seems that mtDNA-encoded subunits are transcribed in a polycistronic fashion and are regulated by the same promoter (excluding ND6) [@pone.0094069-Garbian1], [@pone.0094069-AsinCayuela1]. However, the variation of complex I gene expression response in our study, might be attributed to existence of post-transcriptional regulatory mechanisms and/or differences in mRNA stability among mtDNA-encoded genes. Additionally, post-transcriptional regulation was previously observed for mtDNA-encoded tRNA genes, suggesting that such regulation is not restricted to protein coding mtDNA genes [@pone.0094069-King1].

Conclusions {#s5}
===========

This study provides the first description of the gene expression patterns of 16 OXPHOS complex I subunit genes and the NDUFA4 gene, a subunit of complex IV - a total of 17 genes consisting of seven hallmark mtDNA-encoded genes and ten representative nDNA-encoded subunit genes in FRDA patients compared to controls. The expression of nDNA-encoded subunit genes clustered separately from those of the mtDNA-encoded subunit genes, in which most of the nDNA-encoded subunit genes, such as NDUFA4, NDUFA5, NDUFA10, NDUFA12, NDUFB10, NDUFB11, NDUFC2, NDUFS2, NDUFV1, revealed distinct co-regulated gene expressions, compared to the mtDNA-encoded subunit genes, indicating sub-clustering gene expression. Additionally, the down-regulation of the mtDNA-encoded ND2, ND4L and ND6 subunit genes revealed a divergence, due to mutations, from the rest of the mtDNA-endoded genes regulated by the same promoter. Taken together, our analysis on the mitochondrial complex I gene expression patterns has led to a better understanding of the therapeutic strategies and molecular mechanisms of FRDA in order to predict genetic risk and potentially pave the way for a new diagnostic tool for FRDA patients.
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